EPA is the anti-inflammatory omega-3 — while DHA builds brain structure, EPA fights inflammation. Our research shows EPA is the omega-3 that matters most for depression (meta-analysis: EPA-dominant supplements work, DHA-dominant supplements don't), triglyceride reduction (Vascepa/icosapent ethyl at 4g/day reduced cardiovascular events by 25%), and systemic inflammation (EPA competes with arachidonic acid for COX/LOX enzymes, producing ANTI-inflammatory prostaglandins instead of pro-inflammatory ones). Vascepa (prescription pure EPA) is the first omega-3 FDA-approved for cardiovascular risk reduction based on the landmark REDUCE-IT trial.
EPA (20:5n-3) is a 20-carbon omega-3 that: (1) COMPETES with arachidonic acid (AA, 20:4n-6) for membrane phospholipid incorporation — higher EPA:AA ratio = less inflammatory substrate available; (2) is converted by COX-2 into PGE3 (weakly inflammatory) instead of PGE2 (strongly inflammatory); (3) is converted by 5-LOX into LTB5 (weakly chemotactic) instead of LTB4 (strongly chemotactic); (4) is converted by 15-LOX into resolvin E1/E2 — specialized pro-resolving mediators (SPMs) that actively promote inflammation RESOLUTION (clearing neutrophils, stimulating macrophage efferocytosis); (5) suppresses NF-κB activation via GPR120 receptor. For depression: EPA reduces neuroinflammation (microglial activation) and increases BDNF — both mechanisms relevant to depression pathophysiology.
Based on independent third-party laboratory analysis
Category pass rate: ~90% of fish oil products passed content testing. Rancidity is the primary failure mode — ~10% of products are already oxidized before opening.
Contamination risk: MODERATE. All tested products passed heavy metal testing. Mercury, lead, cadmium all below detection limits. Fish oil purification processes (molecular distillation) effectively remove contaminants.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.
Safety
Dangerous interactions. Talk to your prescriber before using this supplement if you take any of these.
Warfarin (Coumadin)
Omega-3 inhibits platelet aggregation, producing an additive anticoagulant effect on top of warfarin.
Source: PMID: 25062404
Clopidogrel (Plavix)
Dual antiplatelet effect.
Source: FDA label
High-dose Aspirin
Additive antiplatelet effect.
Source: Clinical consensus
Moderate interactions. Monitoring, timing separation, or dose adjustment may be required.
Blood pressure medications
Omega-3 may lower BP modestly.
Source: Clinical consensus
Orlistat (Alli)
Reduces fat absorption, including omega-3.
Source: FDA label
Stop 2 weeks before surgery
Bleeding risk from antiplatelet effect.
Educational information only. This is not medical advice. These statements have not been evaluated by the FDA. Talk to your prescriber before starting, stopping, or combining any supplement with prescription medication.